Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 1

Status

Not yet recruiting 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Recurrence 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma 5Hodgkin Disease 5Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, T-Cell, Peripheral 2Solid Tumor 1Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoblastic Lymphadenopathy 1Carcinoma, Non-Small-Cell Lung 1B-cell Malignancies 1

Interventions

Cyclophosphamide 193fludarabine phosphate 123Peripheral Blood Stem Cell Transplantation 107Etoposide 106Mycophenolic Acid 95Filgrastim 92Doxorubicin 85Whole-Body Irradiation 84Tacrolimus 81Brentuximab Vedotin 80Melphalan 78Busulfan 75Radiotherapy 74fludarabine 68Cyclosporine 67Vinblastine 65Rituximab 60Dacarbazine 56Granulocyte Colony-Stimulating Factor 53Gemcitabine 52Antilymphocyte Serum 51Bleomycin 50Nivolumab 47Methotrexate 47Vincristine 46Prednisone 45Cytarabine 44pembrolizumab 36Carmustine 36Bendamustine Hydrochloride 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Hodgkin Disease × tislelizumab × Lymphoid × Clear all
NCT05502250 2026-03-06

HOVON164HL

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Hodgkin Disease

NCT05977673 2025-12-08

FIL_Tisle-HL

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting
28 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Dalian Medical University

Phase 4 Not yet recruiting
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT05627115 2023-11-29

RATiFY

University College, London

Phase 2 Not yet recruiting
80 enrolled
Lymphoid

Hodgkin Disease

NCT04843267 2021-04-13

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Sun Yat-sen University

Phase 2 Unknown
30 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡